Sign in or Register
  |  

Creative Biolabs has successfully developed SARS, MERS and other anti-viral antibodies in the past to assist scientific research. Facing the difficult COVID-19, Creative Biolabs actively invests in antibody development to assist researchers to better understand the characteristics of 2019-nCoV and drug development. Currently, Creative Biolabs is proud to offer an extensive line of research antibodies to support the study of SARS-CoV-2/COVID-19, several of which were validated using virus-infected cell lysates.

Explore the collections of SARS-CoV-2/COVID-19 antibodies >

Human GALNT2 Peptide (VAEDRTRVV) (PEP-129758CQ)

This product is synthetic peptide that is derived from Human GALNT2 (AA 241-249). This peptide sequence corresponds to amino acid residues: VAEDRTRVV.
Specificity
Human
Format
Lyophilized powder
Storage
Store at -20°C
Introduction
This gene encodes a member of the glycosyltransferase 2 protein family. Members of this family initiate mucin-type O-glycoslation of peptides in the Golgiapparatus. The encoded protein may be involved in O-linked glycosylation of the immunoglobulin A1 hinge region. This gene may influence triglyceride levels, and may be involved Type 2 diabetes, as well as several types of cancer. Alternative splicing results in multiple transcript variants.
Alternative Name
Polypeptide N-Acetylgalactosaminyltransferase 2; Polypeptide GalNAc Transferase 2; UDP-N-Acetyl-Alpha-D-Galactosamine:Polypeptide N-Acetylgalactosaminyltransferase 2 (GalNAc-T2); UDP-GalNAc:Polypeptide N-Acetylgalactosaminyltransferase 2; Pp-GaNTase 2; EC
Entrez Gene ID
UniProt ID
Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Submit a review Submit a review and you will get a coupon.
0 reviews
Loading...

Please try the standard protocols which include: protocols, troubleshooting and guide.

Click here to view the protocols, troubleshooting and guide.

Cat PEP-129758CQ
Conjugates
Size
Price $
  ADD TO CART
Request bulk or custom quote
Second antibody and isotype control